The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study

[1]  Jaw-Yuan Wang,et al.  Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy , 2023, Oncology research.

[2]  M. Arisi,et al.  Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer , 2022, International journal of molecular sciences.

[3]  Jaw-Yuan Wang,et al.  Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment , 2021, Frontiers in Oncology.

[4]  Ruoyu Wang,et al.  Case Report: Vemurafenib Treatment in Brain Metastases of BRAFS365L-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection , 2021, Frontiers in Oncology.

[5]  R. Bernards,et al.  Precision oncology in metastatic colorectal cancer — from biology to medicine , 2021, Nature Reviews Clinical Oncology.

[6]  J. Meyerhardt,et al.  Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  A. Bardelli,et al.  Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients , 2019, ESMO Open.

[8]  Jeffrey W. Clark,et al.  Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers , 2019, Nature Medicine.

[9]  E. Giovannucci,et al.  Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies , 2019, Nature Reviews Gastroenterology & Hepatology.

[10]  Jaw-Yuan Wang,et al.  Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol , 2019, BMC Cancer.

[11]  R. Danesi,et al.  Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial , 2019, JAMA oncology.

[12]  A. Bardelli,et al.  Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Meyerhardt,et al.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.

[14]  Su-Jin Shin,et al.  Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping , 2017, PloS one.

[15]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[17]  Zefeng Wang,et al.  SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling , 2017, Cell Research.

[18]  M. Hidalgo,et al.  Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab , 2016, Oncotarget.

[19]  Jaw-Yuan Wang,et al.  Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer1 , 2016, Translational oncology.

[20]  G. Ribas,et al.  Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology , 2016, Oncotarget.

[21]  Sin-Ho Jung,et al.  Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) , 2016, Oncotarget.

[22]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[23]  M. Kriegsmann,et al.  Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique , 2015, Diagnostic Pathology.

[24]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[25]  Charles Swanton,et al.  Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.

[26]  Shung-Haur Yang,et al.  Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors , 2014, Annals of Surgical Oncology.

[27]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[28]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[29]  S. Jeffrey,et al.  Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis , 2013, Expert review of molecular diagnostics.

[30]  A. Stein,et al.  New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy , 2013, Drugs.

[31]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[32]  T. Cartwright.  Treatment decisions after diagnosis of metastatic colorectal cancer. , 2012, Clinical colorectal cancer.

[33]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[34]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[35]  M. Mimeault,et al.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers , 2007, Journal of cellular and molecular medicine.

[36]  M. Ychou,et al.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.

[37]  S. Umansky,et al.  Circulating Nucleic Acids and Apoptosis , 2001, Annals of the New York Academy of Sciences.

[38]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[39]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[40]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.